The unusual history and the urological applications of botulinum neurotoxin

Urologia Internationalis

Volumn 85, Issue 2, 2010, Pages 125-130

  Hanchanale, Vishwanath S ^a   Rao, Amrith Raj ^b   Martin, Francis L ^c   Matanhelia, Shyam S ^a  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b WEXHAM PARK HOSPITAL   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Botulinum neurotoxin; Detrusor overactivity; Detrusor sphincter dyssynergia; Historical aspects; Prostate; Urology

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; POISON;

BLADDER INJURY; BLADDER NECK STENOSIS; BOTULISM; CHRONIC PAIN; CLINICAL EFFECTIVENESS; COSMETIC INDUSTRY; CYSTALGIA; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FOOD POISONING; GERMANY; HISTORY OF MEDICINE; HUMAN; INTERSTITIAL CYSTITIS; LD 50; LOWER URINARY TRACT SYMPTOM; MEAT; MICTURITION DISORDER; NEUROGENIC BLADDER; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; SPINAL CORD INJURY; URETHRA INJURY; URETHRAL SPASM; URINE INCONTINENCE; URINE RETENTION;

BOTULINUM TOXINS; BOTULISM; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; TREATMENT OUTCOME; URETHRA; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY RETENTION; URINATION DISORDERS; UROLOGY;

EID: 77957286101     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317517     Document Type: Review

References (45)

1. Smith CP, Somogyi GT, Chancellor MB: Botulinum toxin: Poisoning the spastic bladder and urethra. Rev Urol 2002; 4: 61-68.
2. Kerner J: Vergiftung durch verdorbene würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde 1817; 3: 1-25.
3. Kerner J: Neue beobachtungen über die in württemberg so häufig vorfallenden tödlichen vergiftungen durch den genuss geräucherter würste. Tübingen, Oisander, 1820.
4. Kerner J: Das fettgift oder die fettsäure und ihre wirkungen auf den thierischen organismus, ein beytrag zur untersuchung des in verdorbenen würsten giftig wirkenden stoffes. Tübingen, Cotta, 1822.
5. van Ermengem E: Ueber einen neuen anaeroben bacillus und seine beziehungen zum botulismus. Zeitschrift für Hygiene und Infektionskrankheiten 1897; 26: 1-56.
6. Snipe PT, Sommer H: Studies on botulinus toxin. 3. Acid precipitation of botulinustoxin. J Infect Dis 1928; 43: 152-160.
7. Schantz EJ, Johnson EA: Botulinum toxin: The story of its development for the treatment of human disease. Perspect Biol Med 1997; 40: 317-327. (Pubitemid 127753904)
8. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-1049. (Pubitemid 10021090)
9. Dodick DW, Mauskop A, Elkind AH, De- Gryse R, Brin MF, Silberstein SD: Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebocontrolled study. Headache 2005; 45: 315-324. (Pubitemid 40530195)
10. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-922.
11. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023-1029. (Pubitemid 26052703)
12. Litwiller SE, Frohman EM, Zimmern PE: Multiple sclerosis and the urologist. J Urol 1999; 161: 743-757.
13. Elliott DS, Boone TB: Recent advances in the management of the neurogenic bladder. Urology 2000; 56: 76-81.
14. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B: European experience of 200 cases treated with botulinum- A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-515. (Pubitemid 38376219)
15. Kuo HC: Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 2003; 170: 1908-1912. (Pubitemid 37254958)
16. Kuo HC: Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003; 61: 550-554.
17. Flynn MK, Webster GD, Amundsen CL: The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004; 172: 2316-2320.
18. Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A: Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. J Urol 2006; 176: 1767-1770, discussion 1770. (Pubitemid 44291729)
19. Schurch B, de Seze M, Denys P, Chartier- Kastler E, Haab F, Everaert K, Plante P, Perrouin- Verbe B, Kumar C, Fraczek S, Brin MF: Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200. (Pubitemid 40825713)
20. Giannantoni A, Mearini E, Del Zingaro M, Porena M: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results. Eur Urol 2008; 7: 212.
21. Grosse J, Kramer G, Stohrer M: Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-659. (Pubitemid 40521915)
22. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B: Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006; 68: 1193-1197. (Pubitemid 44880353)
23. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E: Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007; 52: 1729-1735. (Pubitemid 350064538)
24. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001; 165: 1107-1110. (Pubitemid 32210212)
25. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R: Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 1998; 79: 715-717. (Pubitemid 28265727)
26. Wheeler JS Jr, Walter JS, Chintam RS, Rao S: Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 1998; 21: 227-229. (Pubitemid 128735592)
27. de Seze M, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM, Barat M: Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 2002; 42: 56-62. (Pubitemid 35339646)
28. Schurch B, Hodler J, Rodic B: Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 1997; 63: 474-476. (Pubitemid 27423554)
29. Cruz F, Silva C: Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Curr Opin Urol 2004; 14: 329-334. (Pubitemid 39506924)
30. Chuang YC, Smith CP, Somogyi GT, Chancellor MB: Botulinum toxin treatment of urethral and bladder dysfunction. J Formos Med Assoc 2003; 102: 5-11. (Pubitemid 36656413)
31. Pannek J, Gocking K, Bersch U: Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 2009; 104: 1246-1250.
32. Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, Knispel HH: Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure. Int J Urol 2008; 15: 407-415, discussion 415. (Pubitemid 351623889)
33. Smith CP: Botulinum toxin in the treatment of OAB, BPH, and IC. Toxicon 2009; 54: 639-646.
34. Kuo HC, Chancellor MB: Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009; 104: 657-661.
35. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M: Two-year efficacy and safety of botulinum A toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr Drug Deliv 2010; 7: 1-4.
36. Zermann D, Ishigooka M, Schubert J, Schmidt RA: Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000; 38: 393-399.
37. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003; 62: 259-264. (Pubitemid 36952073)
38. Kuo HC: Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 670-674.
39. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66: 775-779. (Pubitemid 41440823)
40. Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, Chancellor MB: Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006; 175: 1158-1163. (Pubitemid 43200121)
41. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, Silva C, Cruz F, Dinis P: Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: Duration of the effect of a single treatment. BMC Urol 2009; 9: 9.
42. Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008; 54: 765-775.
43. Kuo HC, Liu HT: Therapeutic effects of addon botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009; 43: 206-211.
44. Smith CP, Somogyi GT, Chancellor MB: Botulinum toxin treatment of urethral and bladder dysfunction. Int Braz J Urol 2002; 28: 545-552. (Pubitemid 36322473)
45. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox-induced prostatic involution. Prostate 1998;37:44-50. (Pubitemid 28385184)